6,7-dimethyl-1-benzofuran | 35355-36-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 6,7-dimethyl-1-benzofuran
• 英文别名: 6,7-dimethylbenzofuran
• CAS: 35355-36-3
• 化学式: C₁₀H₁₀O
• 分子量: 146.189
• InChiKey: OMEUGZPBAFYWGX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  13.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6,7-dimethyl-1-benzofuran 在 正丁基锂 、 3-苄基羟乙基甲基噻唑氯化锂 、 三乙胺 作用下， 以 四氢呋喃 、 正己烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.25h， 生成 Methyl 4-[4-(6,7-dimethyl-1-benzofuran-2-yl)-4-oxobutanoyl]benzoate
  参考文献：
  名称：

  Discovery of Novel and Potent Retinoic Acid Receptor α Agonists:  Syntheses and Evaluation of Benzofuranyl-pyrrole and Benzothiophenyl-pyrrole Derivatives

  摘要：

  In the course of our studies on retinoic acid receptor (RAR) agonists, we have designed and synthesized a series of benzofuran and benzothiophene derivatives. Some of these compounds (1a,b,e,f,j) markedly inhibited LPS-induced B-lymphocyte proliferation and exerted RAR alpha selectivity. One of them, 4-[5-(4,7-dimethylbenzofuran-2-yl)pyrrol-2-yl]benzoic acid (1b), when orally administered significantly inhibited mouse antibody production and delayed type hypersensitivity (DTH) responses from a dose of 0.1 mg/kg.

  DOI：

  10.1021/jm000098s
• 作为产物：
  描述：

  二甲酚 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 32.0h， 生成 6,7-dimethyl-1-benzofuran
  参考文献：
  名称：

  通过级联催化对苯并呋喃进行对映和非对映选择性完全氢化

  摘要：

  我们报道了多取代苯并呋喃在一锅级联催化中的对映和非对映选择性完全氢化。开发的协议有助于受控安装多达六个新定义的立体中心，并产生结构复杂的八氢苯并呋喃，普遍存在于许多生物活性分子中。手性均相钌-N-杂环卡宾络合物和来自络合物前体的原位活化铑催化剂的独特匹配依次作用以实现所提出的过程。

  DOI：

  10.1002/anie.202103910

文献信息

• Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives
  申请人：Galley Guido

  公开号：US20070197621A1

  公开（公告）日：2007-08-23

  The present invention relates a method for treating depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R, R 1 , R 2 , A and n are as defined in the specification and to their pharmaceutically active salts. The invention also relates to novel compounds of formula I, pharmaceutical compositions containing them, and methods for their preparation.

  本发明涉及一种治疗抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍、压力相关障碍、精神分裂症等精神障碍、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用、进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍以及心血管疾病的方法，包括向个体施用化合物I的治疗有效量，其中R、R1、R2、A和n如规范中所定义，以及其药用活性盐。该发明还涉及化合物I的新颖化合物、含有它们的药物组合物以及它们的制备方法。
• SULTAM DERIVATIVES
  申请人：MAEKAWARA Naomi

  公开号：US20090192154A1

  公开（公告）日：2009-07-30

  A sultam derivative of Formula (1) described below having inhibitory action for aggrecanase activity is provided. The sultam derivative of Formula (1) and a salt thereof exhibit strong inhibitory action for aggrecanase activity in a living body of a mammalian animal including human, and is useful, for example, as an active ingredient of a pharmaceutical agent for preventing and/or treating various diseases caused by degradation of aggrecan.

  提供一种以下式（1）描述的磺酰胺衍生物，具有对聚集素酶活性的抑制作用。该式（1）的磺酰胺衍生物及其盐在哺乳动物包括人类的活体内表现出对聚集素酶活性的强抑制作用，并且可用作制药剂的活性成分，用于预防和/或治疗由聚集素降解引起的各种疾病。
• C-glycoside derivatives and salts thereof
  申请人：Imamura Masakazu

  公开号：US20060122126A1

  公开（公告）日：2006-06-08

  The present invention provides C-glycoside derivatives and salts thereof, wherein B ring is bonded to A ring via —X— and A ring is directly bonded to the glucose residue, and it is usable as a Na + -glucose cotransporter inhibitor, especially for a therapeutic and/or preventive agent for diabetes such as insulin-dependent diabetes (type 1 diabetes) and insulin-independent diabetes (type 2 diabetes), as well as diabetes related diseases such as an insulin-resistant diseases and obesity.

  本发明提供了C-糖苷衍生物及其盐，其中B环通过—X—与A环连接，并且A环直接与葡萄糖残基连接，可用作Na+-葡萄糖共转运体抑制剂，特别是用于治疗和/或预防糖尿病，如胰岛素依赖性糖尿病（1型糖尿病）和胰岛素非依赖性糖尿病（2型糖尿病），以及与糖尿病相关的疾病，如胰岛素抵抗性疾病和肥胖症。
• HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS
  申请人：Nishino Taito

  公开号：US20120128640A1

  公开（公告）日：2012-05-24

  An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy useful for treatment of various disorders is provided. An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells containing a compound represented by the formula (I) (wherein X, Y, Z, Ar 1 , R 1 , R 2 , R 3 , R 4 , R 5 , R6 and R 7 are as defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof, which can expand hematopoietic stem cells and/or hematopoietic progenitor cells.

  提供一种用于改善基因治疗中将基因转移至造血干细胞以治疗各种疾病的血液干细胞和/或造血祖细胞扩张剂。该扩张剂包含由式(I)表示的化合物（其中X、Y、Z、Ar1、R1、R2、R3、R4、R5、R6和R7如描述中所定义）、该化合物的互变异构体、前药或药学上可接受的盐或其溶剂，能够扩张血液干细胞和/或造血祖细胞。
• INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
  申请人：Gilead Sciences, Inc.

  公开号：US20130190491A1

  公开（公告）日：2013-07-25

  Compounds of formula I: wherein c, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are defined herein, are useful as inhibitors of HIV replication.

  式I的化合物：其中c，R2，R3，R4，R5，R6，R7和R8如本文所定义，可用作HIV复制的抑制剂。